Objectives: To analyse information about virological testing of cadaveric tissue donors, including the kits used and the rates of test reactivity. Materials and Methods: Retrospective data were collected using a standardised questionnaire sent to 16 tissue banks in the UK. The rates of repeat reactive screen tests and confirmed positive results for the markers HBsAg, anti-HCV, anti-HIV were analysed in 1,833 cadaver tissue donors tested at 12 tissue banks over one year up to March 1998. Results: There was a wide range of kits in use for virological screen testing of cadaver donors. The rates of repeat reactivity in the screen tests varied from 0 to 42%. Conclusion: The findings have implications for policies based on discard of tissues from donors with repeat reactive results, and raise important safety issues with regards to cadaveric virological testing, as the test systems in use have not been validated for cadaver blood samples.

1.
Warwick RM, Eastlund T, Fehily D: Role of the blood transfusion service in tissue banking. Vox Sang 1996;71:71–77.
2.
Kalter ESJ, de By TMMH: Tissue banking programmes in Europe. Br Med Bull 1997;53:798–816.
3.
Michaud RJ, Drabu KJ: Bone allograft banking in the United Kingdom. J Bone Jt Surg 1994;76B:350–351.
4.
Eastlund T: Infectious disease transmission through cell, tissue and organ transplantation: Reducing the risk through donor selection. Cell Transplant 1995;4:455–477.
5.
Kearney JN: Quality issues in skin banking: A review. Burns 1998;24:299–305.
6.
Healing TD, Hoffman PN, Young SEJ: The infection hazards of human cadavers. CDR Rev Commun Dis Rep 1995;5:R61–R68.
7.
Ball J, Desselberger U, Whitwell H: Long-lasting viability of HIV after patient’s death. Lancet 1991;338:63.
8.
Clarke JA: HIV transmission and skin grafts (letter). Lancet 1987;1:983.
9.
Simonds RJ, Holmberg SD, Hurwitz RL, Coleman TR, Bottenfield S, Conley LJ, Kohlenberg SH, Castro KG, Dahan BA, Schable CA, Rayfield MA, Rogers MF: Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 1992;326:726–732.
10.
Conrad EU, Gretch D, Obermeyer KR, Moogk M, Sayers M, Wilson J, Strong DM: The transmission of hepatitis C virus by tissue transplantation. J Bone Joint Surg 1995;77A:214–224.
11.
Novick SL, Schrager JA, Nelson JA, Anderson ME, Baskin BL: Comparison of two hepatitis B surface antigen and two HIV-1 (p24) antigen enzyme immunoassay kits using hemolyzed cadaveric blood specimens. Transplant Proc 1996;28:2925–2926.
12.
Lefor WM, Shires DL, McGonigle AF, Shires DL: Hemoconcentration prior to serology testing in hemodiluted cadaver bone and tissue donors. Clin Transplant 1995;9:297–300.
13.
Heim A, Wagner D, Rothamel T, Hartmann U, Flik J, Verhagen W: Evaluation of serological screening of cadaveric sera for donor selection for cornea transplantation. J Med Virol 1999;58:291–295.
14.
Burtonboye G, Delloye C: Polymerase chain reaction in cadaveric blood and tissues. Transplant Proc 1996;28:2927–2928.
15.
Gala JL, Vandembroucke At, Vandercam B, Pirnay JP, Delferrière N, Burtonboye G: HIV-1 detection by nested PCR and viral culture in fresh or cryopreserved postmortem skin: Potential implications for skin handling and allografting. J Clin Pathol 1997;50:481–484.
16.
British Association of Tissue Banks: Guidelines for Tissue Donor Selection. BATB 1999, www.batb.org.uk.
17.
The American Association of tissue Banks: ‘Standards for Tissue Banks’. AATB 1998, www.aatb.org.
18.
Guidelines for the Blood Transfusion Services in the UK. Section 4, ed 4. 2000, www.thestationaryoffice.com.
© 2000 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.